王育  /  主任医师

—— 博士生导师 ——

学术型博导/专业型博导

—— 博士生招生专业 ——

妇产科学

—— 硕士生导师 ——

学术型硕导/专业型硕导

—— 硕士生招生专业 ——

妇产科学

—— 研究方向 ——

卵巢癌的临床及基础研究，包括但不限于卵巢癌的早筛策略、肿瘤标志物探索及预测模型构建、耐药机制研究、新型靶向药的研发、肿瘤免疫微环境探究和免疫治疗等。

—— 学术任职 ——

国家妇产疾病临床医学研究中心上海分中心 负责人 中国医药教育协会妇科肿瘤专业委员会 主任委员 中华医学会妇科肿瘤分会委员 中国研究型医院协会常务理事 中国医师协会医学机器人医师分会委员 上海医学会妇产科分会副主任委员 上海市医师协会妇产科医师分会副会长

—— 科研项目 ——

2024.12.1-2029.11.31 探索靶向代谢异常的重大疾病诊断新策略 科技部重大专项子课题 2023.8.1-2026.7.31 铂敏感首次复发性卵巢癌的精准治疗策略研究 浦东卫健委 2023.6.1-2024.5.30 女性全生命周期健康科普基地场馆建设项目 浦东科经委 2022.8 - 2023.7 面向妇科肿瘤的CT与MR智能图像质控及设备协同管理平台建设 上海申康医院发展中心 2022.7.1-2024.9.30 超细免膨宫一次性使用半柔性电子宫腔内窥镜的研发与临床研究 上海申康医院发展中心 2022.12.1-2023.3.31 子宫内膜癌综合诊治SOP建设方案 上海医学创新发展基金会 2022.8.1-2025.7.31 质谱多组学检测及指纹图谱分析在卵巢癌诊治中的应用实践 申康新兴前沿技术联合攻关项目 2023.01-2026.12 BCAT2的甘油-3-磷酸修饰致支链氨基酸富集促进上皮性卵巢癌PARP抑制剂耐药的分子机制研究 国家自然科学基金面上项目

—— 学术论文 ——

1. Polystyrene nanoparticle exposure accelerates ovarian cancer development in mice by altering the tumor microenvironment. Sci Total Environ. 2023. 167592((IF=9.8, JCR 一区) 2. Liquid Biopsy for Ovarian Cancer using Circulating Tumor Cells: Recent Advances on the Path to Precision Medicine. 2022，2;9:701429. [J]. BBA-Reviews on Cancer (IF=11.414, JCR 一区) 3. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. 2021，7;1875(2):188503 [J]. BBA-Reviews on Cancer (IF=11.414, JCR 一区) 4. Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics. 2021，11(2):e292 [J]. Clinical and translational medicine (IF=8.554, JCR 一区) 5. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. 2021;1877(1):188660 [J]. Frontiers in cell and developmental biology (IF=6.081, JCR 一区) 6. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. 2021，6540 [J]. Scientific reports (IF=4.996 , JCR 一区) 7. Artificial Intelligence Based on Blood Biomarkers including CTCs Predicts Outcomes in Epithelial Ovarian Cancer: A Prospective Study. 2021，14: 3267–3280. [J]. OncoTargets and therapy (IF=4.345, JCR 二区) 8. Artificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian Cancer. 2020, 7: 1903301. [J] . Advanced science (Weinheim, Baden-Wurttemberg, Germany) (IF=17.521, JCR 一区) 9. Circular RNA hsa_circ_0078607 suppresses ovarian cancer progression by regulating miR-518a-5p/Fas signaling pathway. 2020, 13: 64. [J]. Journal of ovarian research (IF=5.506 , JCR 一区) 10. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination. 2019, 40: 1492-1503. [J] .Carcinogenesis (IF=4.741 , JCR 一区) 11. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. 2018, 125: 469-477.[J] .BJOG (IF=7.331 , JCR 一区) 12. Artificial intelligence algorithm for preoperative prediction of FIGO stage in ovarian cancer based on clinical features integrated 18F-FDG PET/CT metabolic and radiomics features. J Cancer Res Clin Oncol. 2025 Feb 20;151(2):87. 13. A Neutrophil Extracellular Traps-Related Signature Predicts Clinical Outcomes and Identifies Immune Landscape in Ovarian Cancer. J Cell Mol Med. 2024 Dec;28(24):e70302. 14. Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader. Cell Death Dis. 2024 Dec 18;15(12):898. 15. Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189221. 16. PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells. Cell Death Dis. 2024 Aug 22;15(8):610. 17. Boosted photo-immunotherapy via near-infrared light excited phototherapy in tumor sites and photo-activation in sentinel lymph nodes. Nanoscale Adv. 2024 Mar 5;6(8):2075-2087. 18. Identification of the prognostic value of LACTB2 and its correlation with immune infiltrates in ovarian cancer by integrated bioinformatics analyses. Eur J Med Res. 2024 Mar 12;29(1):166. 19. Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer. BMC Cancer. 2024 Feb 26;24(1):267. 20. Pre-fusion motion state determines the heterogeneity of membrane fusion dynamics for large dense-core vesicles. Acta Physiol (Oxf). 2024 Apr;240(4):e14115. 21. Multitask prediction models for serous ovarian cancer by preoperative CT image assessments based on radiomics. Front Med (Lausanne). 2024 Feb 6;11:1334062. 22. Anoikis-related signature predicts prognosis and characterizes immune landscape of ovarian cancer. Cancer Cell Int. 2024 Feb 3;24(1):53. 23. Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9. Biomolecules. 2023 Nov 30;13(12):1724. 24. CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1. Cell Oncol (Dordr). 2024 Jun;47(3):897-915. 25. Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer. Cancer Cell Int. 2023 Oct 6;23(1):232. 26. Endoplasmic Reticulum Stress-Related Ten-Biomarker Risk Classifier for Survival Evaluation in Epithelial Ovarian Cancer and TRPM2: A Potential Therapeutic Target of Ovarian Cancer. Int J Mol Sci. 2023 Sep 12;24(18):14010. 27. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer. J Ovarian Res. 2023 Sep 20;16(1):196. 28. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer. J Ovarian Res. 2023 Apr 29;16(1):86. 29. Construction and validation of a novel ferroptosis-related signature for evaluating prognosis and immune microenvironment in ovarian cancer. Front Genet. 2023 Jan 5;13:1094474. 30. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023 Jan 7;16(1):6.

—— 其他成果 ——

2022年度上海医学科技奖一等奖 2023年上海科普教育创新奖科普贡献奖（个人）一等奖 上海市领军人才 政府特殊津贴获得者 全国荣耀医者奖 上海仁心医师 上海医务工匠